Hypermethylation of multiple tumor-related genes associated with DMNT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma

This study was designed to determine the significance of DNA methyltransferases (DNMTs) in DNA hypermethylation in esophageal squamous cell carcinoma (ESCC) and to identify DNA methylation markers in serum for the early diagnosis of ESCC. A promoter methylation profile of 12 tumor-related genes was assessed using methylation-specific PCR in ESCC and paired non-tumor tissue samples from 47 patients. Expression levels of DNMTs were examined by real-time reverse transcription-PCR and immunohistochemistry. Using MethyLight, the methylation status of 5 genes was analyzed in serum samples from 45 patients and 15 healthy individuals. A total of 46 (97.9%) of 47 ESCC samples showed methylation in at least one of the examined genes, and methylation was most frequent for RAR-β (46.8%), DAPK (46.8%), p16 (44.7%), and CDH1 (42.6%). Methylation of RASSF1A was significantly correlated with the poorly differentiated tumors and the early pathologic tumor classification (P=0.035 and P=0.046, respectively). Tumoral DNMT3b mRNA up-regulation was significantly correlated with hypermethylation of multiple tumor-related genes (P=0.021). In addition, hypermethylation of cell-free serum DNA was common in ESCC patients, and diagnostic accuracy was increased when methylation of multiple genes (RAR-β, DAPK, CDH1, p16 and RASSF1A) were analyzed in combination (ROC AUC 0.911, 82.2% sensitivity and 100% specificity). The present study suggests that hypermethylation of multiple tumor-related genes may be involved in the pathogenesis of ESCC and mediated by the increase of DNMT3b expression. A cluster of multiple methylated genes in serum DNA has the potential as a novel biomarker for ESCC diagnosis.

[1]  I. Bièche,et al.  Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  J. Minna,et al.  The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14ARF, p16INK4a and RASSF1A in human lung cancer cell lines , 2002, Oncogene.

[3]  R. Xavier,et al.  Identification of a Novel Ras-Regulated Proapoptotic Pathway , 2002, Current Biology.

[4]  P. Albers,et al.  CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. , 2009, The Journal of urology.

[5]  C. Croce,et al.  Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  R. Jaenisch,et al.  Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. , 2007, Genes & development.

[7]  A. Nakao,et al.  Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[9]  E. Munck‐Wikland,et al.  Tumor markers carcinoembryonic antigen, CA 50, and CA 19‐9 and squamous cell carcinoma of the esophagus pretreatment screening , 1988, Cancer.

[10]  N. Hu,et al.  Genetic progression and heterogeneity associated with the development of esophageal squamous cell carcinoma. , 2001, Cancer research.

[11]  Qinghua Feng,et al.  Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Danenberg,et al.  Plasma DNA is more reliable than carcinoembryonic antigen for diagnosis of recurrent esophageal cancer. , 2008, Journal of the American College of Surgeons.

[13]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[14]  R. Langer,et al.  The prognostic impact of O6‐Methylguanine‐DNA Methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma , 2006, International journal of cancer.

[15]  S. Hirohashi,et al.  DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. , 2006, Carcinogenesis.

[16]  E. Cho,et al.  CpG island hypermethylation of E‐cadherin (CDH1) and integrin α4 is associated with recurrence of early stage esophageal squamous cell carcinoma , 2008, International journal of cancer.

[17]  J. Foekens,et al.  Methylated genes as new cancer biomarkers. , 2009, European journal of cancer.

[18]  W. Jones,et al.  DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines , 2008, Molecular Cancer.

[19]  Su Jeong Song,et al.  The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC–Cdc20 complex , 2004, Nature Cell Biology.

[20]  J. Herman,et al.  Accumulation of Promoter Methylation Suggests Epigenetic Progression in Squamous Cell Carcinoma of the Esophagus , 2006, Clinical Cancer Research.

[21]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[22]  N. Ahuja,et al.  Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. Yu,et al.  DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma. , 2006, Cancer letters.

[24]  C. Croce,et al.  Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. , 2003, Cancer research.

[25]  P. Malfertheiner,et al.  Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. , 2007, Neoplasia.

[26]  L. Wang,et al.  p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. , 1994, Cancer research.

[27]  Peter W. Laird,et al.  DNA Methylation Profiles of Ovarian Epithelial Carcinoma Tumors and Cell Lines , 2010, PloS one.

[28]  Ya‐Wen Cheng,et al.  An association of DNMT3b protein expression with P16INK4a promoter hypermethylation in non-smoking female lung cancer with human papillomavirus infection. , 2005, Cancer letters.

[29]  Fumiaki Sato,et al.  CpG island hypermethylation in progression of esophageal and gastric cancer , 2006, Cancer.

[30]  N. Matsubara,et al.  Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa , 2006, Gut.

[31]  M. Kaminishi,et al.  The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history , 2009, Cancer.

[32]  Rachel Jones,et al.  Behavioural genetics: Worms gang up on bacteria , 2002, Nature Reviews Genetics.

[33]  P. Laird,et al.  CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. , 1999, Cancer research.

[34]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[36]  B. Christensen,et al.  Aging and Environmental Exposures Alter Tissue-Specific DNA Methylation Dependent upon CpG Island Context , 2009, PLoS genetics.